Temasek Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History

Temasek Holdings’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-126,351	Closed	-$47.2M	–	55
2018 Q4	$47.2M	Hold	126,351	–	–	0.32%	41
2018 Q3	$51.1M	Sell	126,351 -64,270	-34%	-$24.5M	0.3%	41
2018 Q2	$65.8M	Hold	190,621	–	–	0.35%	40
2018 Q1	$65.6M	Hold	190,621	–	–	0.36%	36
2017 Q4	$71.7M	Hold	190,621	–	–	0.44%	32
2017 Q3	$85.2M	Buy	190,621 +13,068	+7%	+$6.22M	0.5%	26
2017 Q2	$87.2M	Buy	177,553 +51,202	+41%	+$22.4M	0.56%	24
2017 Q1	$49M	Hold	126,351	–	–	0.37%	24
2016 Q4	$46.4M	Hold	126,351	–	–	0.37%	24
2016 Q3	$50.8M	Hold	126,351	–	–	0.41%	19
2016 Q2	$44.1M	Hold	126,351	–	–	0.34%	19
2016 Q1	$45.5M	Buy	126,351 +68,062	+117%	+$28M	0.36%	19
2015 Q4	$31.6M	Buy	+58,289	New	+$31.6M	0.24%	22

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Temasek Holdings's REGN Position: Q1 2019 in Review

Temasek Holdings sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 126,351 shares — an estimated $47.2M sold.

Temasek Holdings first reported a position in REGN in Q4 2015 and held it in 13 quarters. The position peaked at $87.2M in Q2 2017. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

Temasek Holdings reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Temasek Holdings sold 126,351 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $47.2M.
Temasek Holdings first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 13 quarters.
Temasek Holdings's Regeneron Pharmaceuticals position peaked at $87.2M in Q2 2017.
718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on Temasek Holdings's 13F filing for Q1 2019, filed 15 May 2019.